(Journal of Clinical Oncology) October 10, 2017 - Cancer drug prices at launch have increased in recent years. It is unclear how individual drug prices change over time after launch and what market determinants influence these changes.
Winston Wong, PharmD (Posted: October 19, 2017)
This study is very similar to the study completed by Peter Bach in 2015. Dr Bach looked at the initial cost of the drug when released, and then tracked cost increases. This study confirms his finding. No matter how you slice and dice the data, the bottom line is that we are still an a time of unsustainable cost increases. The next step is to compare the increases in the US vs. Europe.
(Reuters) Oct 18, 2017 - U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc’s Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer.
Sasi (Posted: October 19, 2017)
Who can afford this drug?
(WCLC) Oct 18, 2017 - Physical exercise and psycho-social interventions in patients with advanced stage lung cancer improved functional capacity, which may be linked to quality of life benefits.
Dean Gesme, MD (Posted: October 18, 2017)
Rehabilitation and Pre-habilitation are woefully underutilized by oncologists as adjuncts to the treatments which we prescribe. Patients deserve the opportunity to optimize their physical wellbeing in order to maximize quality of life and minimize treatment related toxicities.
Professor and Director, Division of Hematology Oncology...
